Biopsy of a renal mass: where are we now?

Laguna, M. Pilar; Kümmerlin, Intan P.E.D.; Rioja, Jorge; Rosette, Jean J.M.C.H. de la

doi:10.1097/mou.0b013e32832f0d5a

Cited by 40 publications

(37 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact most authors [24,25,27] describe a greater sensitivity of CB, except Heilbrun et al, who reported a greater sensitivity of FNAB [26]. However, these authors use a 20G needle for CB, unlike most of the others, who used 18G needles; furthermore Heilbrun's case series is not among the largest ones.…”

Section: Discussionmentioning

confidence: 68%

Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 68%

Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases

et al. 2010

View full text Add to dashboard Cite

show abstract

“…34 Laguna and colleagues identified cancer in 71% of repeat biopsies, and 78% of all cases with a non-diagnostic initial biopsy. 45 Thus, an indeterminate initial biopsy should not be taken as reassurance regarding the malignant potential of the mass.…”

Section: N1mentioning

confidence: 99%

Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus

Rendon

Kapoor

Breau

et al. 2014

CUAJ

View full text Add to dashboard Cite

show abstract

“…A recent review by Laguna and colleagues noted that 46.4% of non-diagnostic biopsies were followed by repeat biopsy or surgery; cancer was present in 78.5% of all specimens, including 71% of repeat biopsies. 6 Changes to the American Joint Committee on Cancer (AJCC) staging of renal cell carcinoma (RCC) were recently released in the 7th edition of the AJCC Cancer Staging Manual.…”

Section: Diagnosis and Stagingmentioning

confidence: 99%

Recent developments in kidney cancer

Leveridge

Jewett

2013

CUAJ

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) diagnosis and management have undergone significant shifts in the recent past. The increasing rate of diagnosis of small renal masses, often in patients at high risk of morbidity with operative treatment, has led to studies, trials and discoveries in renal mass biopsy, active surveillance and minimally invasive thermal ablation. At the other end of the disease spectrum, targeted systemic therapies for metastatic RCC have supplanted cytokine-based treatment, with significant benefits to progression and survival. Recent reviews and trials have also cemented the role of partial nephrectomy as standard surgical management for most low-stage masses, and the roles of regional lymphadenectomy and adrenalectomy concomitant with nephrectomy have been clarified. This review aims to highlight recent evidence that has emerged in the management of this complicated oncologic issue. RésuméLe diagnostic d'hypernéphrome et la prise en charge de cette maladie ont fait l'objet d'importants changements au cours des dernières années. Le taux accru de cas de petites masses rénales, souvent chez des patients présentant un risque élevé de morbidité avec le traitement chirurgical, a amené la conduite d'études et d'essais qui ont entraîné des découvertes touchant la biopsie des masses rénales, la surveillance active et l'ablation thermique minimalement invasive. À l'autre bout du spectre pathologique, les traitements généraux ciblés de l'hypernéphrome métastatique ont supplanté le traitement à base de cytokines, ce qui a amené des avantages significatifs sur le plan de la progression et de la survie. Des articles de synthèse et des essais récents ont aussi confirmé le rôle de la néphrectomie partielle en tant que prise en charge chirurgicale standard pour la plupart des masses de faible stade, et les rôles de la lymphadénectomie régionale et de la surrénalec-tomie en concomitance avec une néphrectomie ont été clarifiés. Le présent article vise à faire ressortir les données récentes dans la prise en charge de ce problème oncologique complexe. IntroductionThe Canadian Cancer Society and the National Cancer Institute of Canada predict 4800 new kidney cancer diagnoses in 2010, and 1650 Canadian deaths from the disease. Kidney cancer is the most lethal genitourinary cancer, but is also among the most interesting cancers due to recent developments exploiting knowledge about known genetic mutations with targeted systemic therapies, better understanding of the extent of associated chronic kidney disease, the utility of nephron-sparing surgery when treating primary tumours and the significant advances in less invasive therapies.This review is not intended to be an exhaustive assessment of the present state of knowledge of kidney cancer, but is an update on recent clinically relevant developments. Diagnosis and stagingOverall, about 85% of renal masses, presumed to be kidney cancers on imaging studies, are carcinomas at nephrectomy. 2Due in part to this high incidence of cancer, biopsy has not been recommended in...

show abstract

Biopsy of a renal mass: where are we now?

Cited by 40 publications

References 30 publications

Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases

Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases

Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus

Recent developments in kidney cancer

Contact Info

Product

Resources

About